Lung adenocarcinoma with <i>ALK</i> deletion of exons 6-20 with response to sequential ALK inhibitors: a case report.

ABSTRACT:

Background

Anaplastic lymphoma kinase (ALK) rearrangements are well-recognized driver oncogenes in patients with non-small cell lung cancer (NSCLC). ALK internal deletions account for only 0.01% of ALK genomic aberrations in NSCLC cases. Due to this rarity, the therapeutic efficacy of ALK inhibitors in cases harboring ALK internal deletions remains unclear. Herein, we report a case of lung adenocarcinoma harboring ALK deletions of exons 6-20 that responded to alectinib and lorlatinib treatment.

Case description

A 42-year-old woman without a history of smoking was diagnosed with stage IVB lung adenocarcinoma. Initial multiplex reverse transcription-polymerase chain reaction (mRT-PCR) (Amoy Dx Pan Lung Cancer PCR Panel) revealed no act

SUBMITTER: Jinno K 

PROVIDER: S-EPMC12605600 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature